Penetration of prulifloxacin into gynaecological tissues after single and repeated oral administrations

Drugs in R and D

Volumn 8, Issue 6, 2007, Pages 373-381

  Gorlero, Franco ^a   Lorenzi, Paola ^a   Rosignoli, Maria Teresa ^b   Picollo, Rossella ^b   Ruggieri, Alessandro ^b   Barattè, Simona ^c   Dionisio, Paolo ^b  

^a Imperia Hospital   (Italy)

^b Università Politecnica delle Marche ACRAF Gruppo Angelini   (Italy)

^c NERVIANO MEDICAL SCIENCES   (Italy)

Author keywords

Gynaecological infections; Prulifloxacin, pharmacokinetics

Indexed keywords

PRULIFLOXACIN;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; BACTERIAL INFECTION; BLOOD SAMPLING; CALIBRATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENDOMETRIUM; FEMALE; GYNECOLOGY; HOSPITAL PATIENT; HUMAN; HUMAN TISSUE; HYSTERECTOMY; LIQUID CHROMATOGRAPHY; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; TISSUE SECTION; UTERINE TUBE; VAGINA;

EID: 35548941911     PISSN: 11745886     EISSN: None     Source Type: Journal    
DOI: 10.2165/00126839-200708060-00005     Document Type: Article

References (18)

1. Keam SJ, Perry CM. Prulifloxacin. Drugs 2004; 64 (19): 2221-34
2. Tougou K, Nakamura A, Watanabe S, et al. Paraxonase has a major role in the hydrolysis of prulifloxacin (NM441), a prodrug of a new antibacterial agent. Drug Metab Dispos 1998; 26 (4): 355-9
3. Picollo R, Brion N, Gualano V, et al. Pharmacokinetics and tolerability of prulifloxacin after single oral administration. Arzneimittelforschung 2003; 53 (3): 201-5
4. Nakashima M, Uematsu T, Kosuge K, et al. Pharmacokinetics and safety of NM441, a new quinolone, in healthy male volunteers. J Clin Pharmacol 1994; 34: 930-7
5. Gutman RE, Peipert JF, Weitzen S, et al. Evaluation of clinical methods for diagnosing bacterial vaginosis. Obstet Gynecol 2005; 105 (3): 551-6
6. Donders GGG, Vereecken A, Bosmans E, et al. Definition of a type of abnormal vaginal flora that is distinct from bacterial vaginosis: aerobic vaginitis. BJOG 2002; 109: 34-43
7. Leitich H, Kiss H. Asymptomatic bacterial vaginosis and intermediate flora as risk factors for adverse pregnancy outcome. Best Pract Res Clin Obstet Gynaecol 2007 Jun; 21 (3): 375-90
8. Mikamo H, Kawazoe K, Izumi K, et al. NM441: penetration into gynaecological tissues and in vitro activity against clinical isolates from obstetric and gynaecological patients. Drugs 1995; 49 Suppl. 2: 326-30
9. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41
10. Concia E, Allegranzi B, Ciottoli GB, et al. Penetration of orally administered prulifloxacin into human lung tissue. Clin Pharmacokinet 2005; 44 (12): 1287-94
11. Mikamo H, Ninomiya M, Tamaya T. Penetration of oral telithromycin into female genital tissues. J Infect Chemother 2003; 9 (4): 358-60
12. Gerstner GJ, Dalhoff A, Weuta H. Single and multiple dose pharmacokinetics of ciprofloxacin in gynecological tissues. Infection 1988; 16 Suppl. 1: S24-8
13. Lehtonen L, Wikberg R, Karhunen M, et al. Erythromycin and 2′-acetyl erythromycin concentrations in plasma and pelvic tissues after repeated doses of erythromycin acistrate. Arzneimittelforschung 1993; 43 (1): 53-6
14. Martens MG, Maccato M, Van Hook C, et al. Penetration of trovafloxacin into gynecologic tissues. Am J Surg 1998; 176 (6A Suppl.): 18S-22S
15. Montanari MP, Mingoia M, Varaldo PE. In vitro antibacterial activities of AF 3013, the active metabolite of prulifloxacin, against nosocomial and community Italian isolates. Antimicrob Agents Chemother 2001; 45 (12): 3616-22
16. Prats G, Roig C, Mirò E, et al. In vitro activity of the active metabolite of prulifloxacin (AF 3013) compared with six other fluoroquinolones. Eur J Clin Microbiol Infect Dis 2002; 21 (4): 328-34
17. Wispelwey B. Clinical implications of pharmacokinetics and pharmacodynamics of fluoroquinolones. Clin Infect Dis 2005; 41 Suppl. 2: S127-35
18. Barger A, Fuhst C, Wiedemann B. Pharmacological indices in antibiotic therapy. J Antimicrob Chemother 2003; 52 (6): 893-8